Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07622108 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2026 to Sep 28, 2026
    • Eligibility criteria expanded, about 177 words
    • Secondary endpoints: details revised at 4 of 8 entries
  2. Secondary endpoints: details revised at 3 of 8 entries
    • Study description expanded, about 45 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
Trial Details
NCT Number NCT07622108
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions
(from sponsor)		 Thyroid Eye Disease, TED
Related terms Graves Ophthalmopathy
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov